Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%.The Motley Fool • 07/03/26
MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week?Zacks Investment Research • 07/03/26
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?The Motley Fool • 07/03/26
MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond VaccinesZacks Investment Research • 06/29/26
Moderna Is Up 13% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?24/7 Wall Street • 06/26/26
Moderna, Inc. (MRNA) Discusses Advancements in mRNA Technology, Clinical Modalities, and Future Horizons in Science TranscriptSeeking Alpha • 06/26/26
MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel BackingZacks Investment Research • 06/19/26
Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza VaccineAccesswire • 06/18/26